NDA 207999 · Intercept
Ocaliva
Obeticholic Acid · Oral
NovelAccelerated approvalPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Feb 24, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
May 27, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
40
9 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 27, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewSummary Review
2 products under this application
- OCALIVA · OBETICHOLIC ACID 10MG · TABLET, ORAL · Discontinued · TE AB
- OCALIVA · OBETICHOLIC ACID 5MG · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Obeticholic Acid" as an intervention, any sponsor and status, largest first.
- Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid TreatmentPivotal-lookingTerminated
Intercept PharmaceuticalsIndustry
NCT02548351 · 2,477 participants · Start Sep 22, 2015 · Primary completion Sep 15, 2023
Drug: Obeticholic Acid; Placebo · For: Non Alcoholic Steatohepatitis (NASH)
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 346 sites in all
- Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisPivotal-lookingCompleted
Intercept PharmaceuticalsIndustry
NCT03439254 · 919 participants · Start Aug 30, 2017 · Primary completion Sep 8, 2022
Drug: Obeticholic acid (10 mg); Obeticholic acid (10 mg to 25 mg) and 1 more · For: Compensated Cirrhosis; Nonalcoholic Steatohepatitis
Sites: Dothan, Alabama; Madison, Alabama; Chandler, Arizona · 192 sites in all
- Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary CholangitisPivotal-lookingTerminated
Intercept PharmaceuticalsIndustry
NCT02308111 · 334 participants · Start Dec 26, 2014 · Primary completion Dec 23, 2021
Drug: Obeticholic Acid (OCA); Placebo · For: Liver Cirrhosis, Biliary
Sites: Phoenix, Arizona; Los Angeles, California; Rialto, California · 181 sites in all
- The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)Pivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT01265498 · 283 participants · Start Mar 2011 · Primary completion Jan 2014
Drug: obeticholic acid; placebo · For: Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Steatohepatitis (NASH)
Sites: San Diego, California; San Francisco, California; Indianapolis, Indiana · 9 sites in all
- Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary CirrhosisPivotal-lookingCompleted
Intercept PharmaceuticalsIndustry
NCT01473524 · 217 participants · Start Jan 2012 · Primary completion Dec 2013
Drug: Obeticholic Acid (OCA); Placebo · For: Primary Biliary Cirrhosis
Sites: Sacramento, California; San Diego, California; Aurora, Colorado · 59 sites in all
- Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)Pivotal-lookingTerminated
Intercept PharmaceuticalsIndustry
NCT00550862 · 165 participants · Start Oct 2007 · Primary completion Aug 2009
Drug: INT-747; Ursodeoxycholic Acid (URSO) and 1 more · For: Liver Cirrhosis, Biliary
Sites: Gainesville, Florida; Miami, Florida; Boston, Massachusetts · 32 sites in all
- Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)Pivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04956328 · 120 participants (planned) · Start Jul 22, 2021 · Primary completion Sep 20, 2023
Drug: Obeticholic Acid Tablets; UDCA and 1 more · For: Primary Biliary Cirrhosis
Sites: Changchun, China
- Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary CholangitisPivotal-lookingCompleted
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT05450887 · 108 participants · Start Sep 23, 2021 · Primary completion Mar 18, 2024
Drug: Obeticholic Acid Tablets(OCA); UDCA and 1 more · For: Primary Biliary Cholangitis
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ocaliva (Obeticholic Acid)
2024 spending
$185M
Beneficiaries
2,104
16,339 claims
Per beneficiary
$87,912
$310.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $97,483,170 |
| 2021 | $116,167,277 |
| 2022 | $132,584,847 |
| 2023 | $163,801,289 |
| 2024 | $184,965,829 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.
Souza M, Al-Sharif L, Antunes VLJ, et al. · Hepatology 2025 · Systematic Review, Comparative Study
- Nonalcoholic fatty liver disease: a systematic review.
Rinella ME · JAMA 2015 · Systematic Review
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
Nevens F, Andreone P, Mazzella G, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Multicenter Study
- Second-Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta-Analysis.
Giannini EG, Pasta A, Calabrese F, et al. · Liver Int 2025 · Systematic Review, Network Meta-Analysis
- Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials.
Wang Y, Yi H, Sun W, et al. · Drugs 2024 · Comparative Study, Systematic Review
- Obeticholic Acid vs Fibrates as Second-Line Therapy for Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Abreu ES, Reginato PH, Pitanga JFJ, et al. · Dig Dis Sci 2025 · Systematic Review, Meta-Analysis
Sponsor: Intercept
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.